Contact us

Contact us at the address, e-mail or telephone number below and we'll get back to you as soon as possible.

DAVID eHealth & Pharma UG,
Saarland University,
Starterzentrum, Building A1 1,
66123, Saarbruecken
Germany

This email address is being protected from spambots. You need JavaScript enabled to view it.

+49-151-51700933

Didn't we got you connected? Please note the following magic buttons:

Want to place your Ads or News on World Pharma News?

World Pharma News is one of the most visited sites on the Internet for pharmaceutical business decision-makers, professionals and stakeholders looking for the latest breaking news on the global market and in-depth research news articles. Why not put this traffic to work for you? It costs only a fraction of other on-line publications, which have far fewer readers.

We have the solutions that meet your ambitious marketing objectives. We offer flexible and price-worthy advertising opportunities for you to take advantage of. These include:

  • Skyscraper Banner, 120px / 600px (left-top, left-bottom)
  • Medium Rectangle Banner, 300px / 250px (right-top, medium and right-bottom)
  • Standard Banner, 468px / 60px (middle-top and middle-bottom)
  • Leaderboard Banner, 728px / 90px (top and bottom)
  • Newsletter Ads

The strong, innovative capabilities of World Pharma News can support your advertising, news promotion and news distribution campaigns. You will reach your objectives and an unique audience of top pharma professionals, key players and decision makers.

Don't Be Shy. If we didn’t answer all of your questions, feel free to drop us a line anytime.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...